Saeho Chong, PhD | Chief Executive Officer
Dr. Saeho Chong brings more than 25 years of senior management experience, including more than a decade of strategic development in the pharmaceutical industry. He most recently served as Vice President, Early Development at Alnylam Pharmaceuticals, where he had a significant track record of success in R&D.
Previously, he served in roles of increasing responsibility and leadership at Bristol-Myers Squibb and Millennium (Takeda Oncology). He also held a prior position in the U.S. Food and Drug Administration’s (FDA) Office of Clinical Pharmacology and was a professor of Pharmaceutical Sciences, College of Pharmacy at Seoul National University.
Dr. Chong received his B.S. and Ph.D. in Pharmaceutics at the esteemed School of Pharmacy of the State University of New York at Buffalo. He received post-graduate training under the guidance of Dr. HL Fung at SUNY Buffalo and is currently an Adjunct Associate Professor of Pharmaceutical Sciences at SUNY Buffalo. He has held editorial board positions of the American Association of Pharmaceutical Scientists Journal, Drug Metabolism and Pharmacokinetics, Archives of Pharmacal Research, and the Journal of Pharmaceutical Investigation, and has authored more than 90 publications in peer-reviewed journals.
Saeho is a die-hard Buffalo Bills fan and is still working toward his first Hole-In-One.
READ MORE
Seong H. Jang, PhD | Chief Operating Officer
Dr. Seong H. Jang brings a deep expertise in clinical pharmacology, having held considerable positions of increasing responsibility at FDA for nearly 20 years. His experience includes leadership roles in the Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research. He and his team contributed to the approval of an impressive portfolio of new drug products in multiple therapeutic areas, including transplant, special pathogen and anti-infectives.
He is widely recognized both internally and externally for his expertise and collaboration. Further, his contributions include serving as a cross disciplinary team leader in several NDA reviews and as an acting deputy division director for the Office of Study Integrity and Surveillance.
Dr. Jang earned his Ph.D. in biopharmaceutics from the College of Pharmacy at Ohio State University with focus in pharmacokinetics and pharmacodynamics and subsequently as a research fellow. He received his bachelor’s and master’s degrees from the College of Pharmacy at Seoul National University and has published numerous peer-reviewed articles and has often presented at scientific organizations such as the Clinical Trials Transformation Initiative, National Health Institutes, and the American Society for Microbiology.
Seong enjoys running in his free time. He even coordinated an “Elevar Runner’s Club” for an all-staff event.
READ MORE
Wade Smith | Chief Financial & Business Officer
Wade Smith is responsible for Elevar’s capital acquisition and deployment, accounting/controlling, financial planning and analysis, business development and portfolio optimization, marketing, market access, commercial operations and pricing functions in addition to serving as the corporate secretary.
With more than 30 years of experience as a financial and commercial executive, Wade Smith joined Elevar Therapeutics in January 2022 after spending the previous decade at Viatris (formerly Mylan Pharmaceuticals), a global health care company working in a broad range of therapeutic areas. Most recently, Mr. Smith was Viatris’ head of U.S. institutional commercial/finance from 2017-2022, functioning as the COO and CFO for the $1 billion+ division.
He developed a go-to-market strategy for more than 100 new products, overseeing launch pricing, customer contracting, managed care engagement, demand planning, and sales targeting in addition to portfolio selection and budgeting/forecasting. He previously held finance leadership positions of increasing responsibility in the energy industry, at Taggart Global USA, LLC and Nova Chemicals where his work included investor relations, mergers & acquisitions, initial public offerings (S-1), consolidations, and financial planning & analysis.
Wade started his career in public accounting and still holds an active CPA license in the Commonwealth of Pennsylvania. He earned a bachelor’s degree in business administration and accounting from Penn West – California University of Pennsylvania.
He enjoys trail running, hiking, and spending time with his wife and daughter.
READ MORE
Tyler Wiseman | Chief Legal Officer
Tyler Wiseman joined Elevar Therapeutics in May 2022 after serving as corporate counsel for Praxis Precision Medicines Inc. since August 2020. He played a lead role in developing Praxis’s legal infrastructure and strengthening its team, processes, policies and templates, while overseeing legal review and approval of all company contracts. Wiseman was also instrumental in managing the company’s data privacy, intellectual property, employment and litigation law.
Mr. Wiseman holds a J.D. degree from Suffolk University Law School and is admitted to the Massachusetts Bar. He also holds an MBA (magna cum laude) from Endicott College and a bachelor’s degree (magna cum laude) from Northeastern University.
Tyler is a New England Patriots fan and has an adorable chocolate lab named ‘Goose’.
READ MORE
Chris Galloway, M.D. | SVP, Clinical and Medical Affairs
Dr. Chris Galloway is an executive physician with more than 20 years of comprehensive medical practice and biotechnology experience. He joined Elevar in 2023 bringing extensive industry expertise spanning leadership roles in early and late-stage clinical development, medical affairs and business development in oncology and other therapeutic areas. His broad experiences include managing several successful Investigational New Drug Applications (IND), NDA, and BLA submissions to the FDA. In his role at Elevar, he oversees the global Clinical Development, Clinical Operations and Medical Affairs functions.
Most recently, he served as Chief Medical Officer at Diffusion Pharmaceutics where he led all pre-clinical and clinical development, medical affairs, drug safety, pharmacovigilance, medical monitoring and biometrics. Prior industry experience includes leadership roles in medical affairs and clinical development at La Jolla Pharmaceutical, Rakuten Medical, Merck and DaVita Clinical Research. Prior to his professional transition to clinical research, he worked for a decade as an emergency room physician.
Dr. Galloway received a B.S. in Biology from The University of Texas Austin and an M.D. from The University of Texas Medical Branch.
Chris is a Texan at heart, but loves raising his family in the beautiful and rugged outdoors of Colorado.
READ MORE
